Cargando…
Anti-trypanosomatid drug discovery: progress and challenges
Leishmaniasis (visceral and cutaneous), Chagas disease and human African trypanosomiasis cause substantial death and morbidity, particularly in low- and middle-income countries. Although the situation has improved for human African trypanosomiasis, there remains an urgent need for new medicines to t...
Autores principales: | De Rycker, Manu, Wyllie, Susan, Horn, David, Read, Kevin D., Gilbert, Ian H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395782/ https://www.ncbi.nlm.nih.gov/pubmed/35995950 http://dx.doi.org/10.1038/s41579-022-00777-y |
Ejemplares similares
-
Challenges and recent progress in drug discovery for tropical diseases
por: De Rycker, Manu, et al.
Publicado: (2018) -
Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay
por: Svensen, Nina, et al.
Publicado: (2021) -
Oligo targeting for profiling drug resistance mutations in the parasitic trypanosomatids
por: Altmann, Simone, et al.
Publicado: (2022) -
Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects
por: Patterson, Stephen, et al.
Publicado: (2014) -
Comment on “The translational challenge in Chagas disease drug development” by Kratz et al.
por: De Rycker, Manu
Publicado: (2022)